2025
Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Bui D, Hynes D, Rowneki M, Hickok A, Niederhausen M, Shahoumian T, Bohnert A, Boyko E, Korpak A, Fox A, Baraff A, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, Pura J, Hebert P, Wong E, O’Hare A, Osborne T, Viglianti E, Aslan M, Bajema K. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases 2025, ciaf087. PMID: 40208261, DOI: 10.1093/cid/ciaf087.Peer-Reviewed Original ResearchPost-COVID-19 conditionCumulative incidence of deathVeterans Health AdministrationMatched index dateCumulative incidence differenceExcess burdenCumulative incidenceBurden of mortalityHypothetical target trialIncidence of deathDeath up to 1 yearTarget trial emulationAll-Cause MortalityHealth recordsHealth AdministrationTrial emulationIncidence differencesIndex dateUninfected participantsPost-coronavirus diseaseVeteransUnvaccinated personsTarget trialsOmicron eraVaccination statusEffectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Lin H, Bui D, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, O'Hare A, Viglianti E, Aslan M, Bajema K. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation. Annals Of Internal Medicine 2025, 178: 348-359. PMID: 39903865, DOI: 10.7326/annals-24-01015.Peer-Reviewed Original ResearchConceptsU.S. Department of Veterans AffairsDepartment of Veterans AffairsMatched index dateVaccine effectivenessTarget trial emulationSARS-CoV-2-associated deathsRandomized Controlled TrialsCOVID-19 vaccineSARS-CoV-2-related outcomesSARS-CoV-2 testingVeterans AffairsResidual confoundingAbsence of randomized controlled trialsLong-term follow-upDocumented SARS-CoV-2 infectionTrial emulationUnvaccinated personsIndex datePositive resultsControlled TrialsCOVID-19SARS-CoV-2 infectionIncomplete captureHospitalDocumented infection
2024
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Yan L, Bui D, Li Y, Rajeevan N, Rowneki M, Berry K, Argraves S, Huang Y, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. Clinical Infectious Diseases 2024, 79: 643-651. PMID: 38864601, DOI: 10.1093/cid/ciae202.Peer-Reviewed Original ResearchRisk quartileVeterans Health AdministrationLowest risk quartileHighest risk quartileTarget trial emulationRisk prediction modelUntreated veteransRisk of deathOlder veteransYounger veteransHealth AdministrationTrial emulationMeasure IncidenceNirmatrelvir-ritonavirVeteransHospitalUntreated participantsCOVID-19QuartileRiskSevere coronavirus disease 2019ParticipantsPersonsCoronavirus disease 2019Severe COVID-19Self-Reported Everyday Functioning After COVID-19 Infection
Iwashyna T, Smith V, Seelye S, Bohnert A, Boyko E, Hynes D, Ioannou G, Maciejewski M, O’Hare A, Viglianti E, Berkowitz T, Pura J, Womer J, Kamphuis L, Monahan M, Bowling C, Admon A, Akgun K, Anderson S, Aslan M, Au D, Backus L, Bajema K, Baraff A, Batten L, Berkowitz T, Bernstein T, Berry Wyatt K, Bogdan J, Bosworth H, Boucher N, Burwick N, Cabrales A, Cano J, Chai W, Chen J, Cheung K, Crothers K, Curtis J, Davis M, Del Monico E, Dobalian A, Doll J, Dominitz J, Eastment M, Fan V, Ferguson J, Floyd B, Fox A, Goetz M, Govier D, Green P, Hastings S, Hauschildt K, Hawkins E, Hebert P, Helfand M, Hickok A, Horowitz D, Hough C, Hu E, Ikuta K, Jones B, Jones M, Kamphuis L, Kaufman B, Knight S, Korpak A, Korpela P, Kumbier K, Langa K, Laundry R, Lavin S, Li Y, Linquist J, McCready H, Michel M, Miles A, Milne J, Monahan M, Morelli D, Mutalik P, Naylor J, Neiderhausen M, Newell S, Nugent S, Ong M, Osborne T, Peterson M, Peterson A, Prescott H, Rajeevan N, Reddy A, Rouse M, Rowneki M, Saha S, Saini S, Shah J, Shahoumian T, Shaukat A, Shepherd-Banigan M, Showalter W, Slatore C, Smith N, Smith B, Suri P, Sussman J, Takata Y, Teo A, Thomas E, Thomas L, Tuepker A, Veigulis Z, Vig E, Vranas K, Wang X, Wicks K, Winchell K, Wong E, Woods C, Wysham K, Yan L, Zulman D. Self-Reported Everyday Functioning After COVID-19 Infection. JAMA Network Open 2024, 7: e240869. PMID: 38427352, PMCID: PMC10907923, DOI: 10.1001/jamanetworkopen.2024.0869.Peer-Reviewed Original ResearchConceptsEveryday functioningActivities of daily livingSelf-reported everyday functioningCOVID-19 infectionImpact of COVID-19 infectionDaily livingVeterans AffairsCOVID-19 cohortDocumented COVID-19Instrumental activities of daily livingMatched pairs of participantsHealth-related quality of lifePairs of participantsCohort studyProportion of veteransControl cohortLife-space mobilityStudy of veteransCohort study of veteransUS Veterans AffairsHealth-related qualityDocumented COVID-19 infectionSelf-ReportTarget trial emulationQuality of life
2023
Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systems
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply